Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen

被引:0
|
作者
Marilyn L. Kwan
Jiaxiao M. Shi
Laurel A. Habel
Jun Song
Joanie W-L Chung
Chantal C. Avila
Joanne E. Schottinger
T. Craig Cheetham
Suzanne W. Fletcher
Reina Haque
机构
[1] Kaiser Permanente Northern California,Division of Research
[2] Kaiser Permanente Southern California,Department of Research and Evaluation
[3] Kaiser Permanente Northwest,Data & Information Management Enhancement
[4] Kaiser Permanente Southern California,Department of Clinical Analysis
[5] Harvard Medical School and Harvard Pilgrim Health Care Institute,undefined
来源
关键词
Breast cancer; Bisphosphonates; Alendronate; Contralateral breast cancer; Second primary cancers; Cohort study;
D O I
暂无
中图分类号
学科分类号
摘要
The effectiveness of bisphosphonates (BP) in reducing risk of second breast cancer and recurrence in observational studies has been minimally studied. We examined the association of oral BP use on risk of contralateral breast cancer (CBC) and recurrence in 16,781 women diagnosed with early-stage breast cancer from 1996 to 2007, treated with tamoxifen, and followed through December 31, 2009 at Kaiser Permanente Northern California (KPNC, n = 8857) and Southern California (KPSC, n = 7924). Sociodemographic, clinical, and pharmacy information were extracted from electronic medical records and cancer registries. CBC was identified from cancer registries, and recurrences from electronic health records and chart reviews. Multivariate Cox regression models were used to estimate hazard ratios (HR) and 95 % confidence intervals (CI) treating BP use and hormonal therapy as time-varying variables. After mean 6.4 years of follow-up, 494 (3.0 %) women developed CBC. BP use post-breast cancer diagnosis (>93 % alendronate) ranged from 14.5 to 24.9 % at both study sites. Overall, there was no association of BP use with reduced risk of CBC (ever use, HR = 0.96; 95 % CI 0.67–1.38 and continuous use, HR = 1.03; 95 % CI 0.88, 1.20). Similar null associations were observed for recurrence (ever use, HR = 0.98; 95 % CI 0.82, 1.17 and continuous use, HR = 1.00; 95 % CI 0.92, 1.09). Associations varied somewhat by site yet confidence intervals overlapped. BP use was not associated with reduced risk of recurrence or new primary disease among women diagnosed with early breast cancer and treated with tamoxifen.
引用
收藏
页码:379 / 389
页数:10
相关论文
共 50 条
  • [1] Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen
    Kwan, Marilyn L.
    Shi, Jiaxiao M.
    Habel, Laurel A.
    Song, Jun
    Chung, Joanie W-L
    Avila, Chantal C.
    Schottinger, Joanne E.
    Cheetham, T. Craig
    Fletcher, Suzanne W.
    Haque, Reina
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (02) : 379 - 389
  • [2] Local Recurrence Risk Factors in Women Treated With BCT for Early-Stage Breast Cancer
    Dang, Catherine M.
    Giuliano, Armando E.
    [J]. ONCOLOGY-NEW YORK, 2011, 25 (10): : 895 - +
  • [3] Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A population-based study
    Gao, X
    Fisher, SG
    Emami, B
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (04): : 1038 - 1045
  • [4] BMI variation increases recurrence risk in women with early-stage breast cancer
    Fedele, Palma
    Orlando, Laura
    Schiavone, Paola
    Quaranta, Annamaria
    Lapolla, Assunta Maria
    De Pasquale, Maria
    Ardizzone, Antonino
    Bria, Emilio
    Sperduti, Isabella
    Calvani, Nicola
    Marino, Antonella
    Caliolo, Chiara
    Mazzoni, Enrica
    Cinieri, Saverio
    [J]. FUTURE ONCOLOGY, 2014, 10 (15) : 2459 - 2468
  • [5] Disparities in contralateral prophylactic mastectomy use among women with early-stage breast cancer
    Kim, Younji
    McCarthy, Anne Marie
    Bristol, Mirar
    Armstrong, Katrina
    [J]. NPJ BREAST CANCER, 2017, 3
  • [6] Disparities in contralateral prophylactic mastectomy use among women with early-stage breast cancer
    Younji Kim
    Anne Marie McCarthy
    Mirar Bristol
    Katrina Armstrong
    [J]. npj Breast Cancer, 3
  • [7] Dietary Patterns and Breast Cancer Recurrence and Survival Among Women With Early-Stage Breast Cancer
    Kwan, Marilyn L.
    Weltzien, Erin
    Kushi, Lawrence H.
    Castillo, Adrienne
    Slattery, Martha L.
    Caan, Bette J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 919 - 926
  • [8] Risk factors for enduring fatigue in women treated for early-stage breast cancer
    Bardwell, W.
    Dimsdale, J.
    Pierce, J.
    [J]. PSYCHO-ONCOLOGY, 2007, 16 (03) : S21 - S22
  • [10] Risk of contralateral breast cancer after tamoxifen use among Danish women
    Mellernkjaer, Lene
    Steding-Jessen, Marianne
    Frederiksen, Kirsten
    Andersson, Michael
    Ejlertsen, Bent
    Jensen, Maj-Britt
    Olsen, Jorgen H.
    [J]. ANNALS OF EPIDEMIOLOGY, 2014, 24 (11) : 843 - 848